These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38133181)

  • 1. Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine.
    Ceccardi G; Schiano di Cola F; Caratozzolo S; Di Pasquale M; Bolchini M; Padovani A; Rao R
    Toxins (Basel); 2023 Nov; 15(12):. PubMed ID: 38133181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
    Grazzi L; Giossi R; Montisano DA; Canella M; Marcosano M; Altamura C; Vernieri F
    J Headache Pain; 2024 Feb; 25(1):14. PubMed ID: 38308209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
    J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan.
    Wang YF; Yang FC; Chen LA; Chang TY; Su HC; Yang CP; Tu YH; Tzeng YS; Chen SP; Fuh JL; Lai KL; Ling YH; Chen WT; Wang SJ
    Eur J Neurol; 2024 Sep; 31(9):e16372. PubMed ID: 38837528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review.
    Salim A; Hennessy E; Sonneborn C; Hogue O; Biswas S; Mays M; Suneja A; Ahmed Z; Mata IF
    CNS Drugs; 2024 Jun; 38(6):481-491. PubMed ID: 38583127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
    Iannone LF; Fattori D; Marangoni M; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2023 Feb; 37(2):189-202. PubMed ID: 36656298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
    Moskatel LS; Graber-Naidich A; He Z; Zhang N
    Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety.
    Corasaniti MT; Lawrence GW; Bagetta G; Iannacchero R; Tarsitano A; Monteleone A; Pagliaro M; Tonin P; Sandrini G; Nicotera P; Scuteri D
    Front Pharmacol; 2023; 14():1296577. PubMed ID: 38152694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
    Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience.
    Raffaelli B; Fitzek M; Overeem LH; Storch E; Terhart M; Reuter U
    J Headache Pain; 2023 Feb; 24(1):16. PubMed ID: 36843007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study.
    Montisano DA; Giossi R; Canella M; Altamura C; Marcosano M; Vernieri F; Raggi A; Grazzi L
    Toxins (Basel); 2024 Apr; 16(4):. PubMed ID: 38668603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
    Blumenfeld AM; Frishberg BM; Schim JD; Iannone A; Schneider G; Yedigarova L; Manack Adams A
    Pain Ther; 2021 Dec; 10(2):809-826. PubMed ID: 33880725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
    Scuteri D; Tonin P; Nicotera P; Vulnera M; Altieri GC; Tarsitano A; Bagetta G; Corasaniti MT
    Toxins (Basel); 2022 Aug; 14(8):. PubMed ID: 36006191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
    J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Mitsikostas DD
    J Headache Pain; 2016 Dec; 17(1):84. PubMed ID: 27640152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study.
    Alpuente A; Gallardo VJ; Caronna E; Torres-Ferrús M; Pozo-Rosich P
    Eur J Neurol; 2021 Jul; 28(7):2378-2382. PubMed ID: 33730441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
    Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
    Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
    Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
    J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population.
    Lazaro-Hernandez C; Caronna E; Rosell-Mirmi J; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    J Headache Pain; 2024 Feb; 25(1):21. PubMed ID: 38347485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.